238 related articles for article (PubMed ID: 20394503)
1. Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells.
Wang X; Heuvelman DM; Carroll JA; Dufield DR; Masferrer JL
Cancer Invest; 2010 Jul; 28(6):635-41. PubMed ID: 20394503
[TBL] [Abstract][Full Text] [Related]
2. Indirect participation of Hsp90 in the regulation of the cyclin E turnover.
Bedin M; Catelli MG; Cabanié L; Gaben AM; Mester J
Biochem Pharmacol; 2009 Jan; 77(2):151-8. PubMed ID: 18977205
[TBL] [Abstract][Full Text] [Related]
3. Geldanamycin and its anti-cancer activities.
Fukuyo Y; Hunt CR; Horikoshi N
Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
[TBL] [Abstract][Full Text] [Related]
4. CYP2E1 degradation by in vitro reconstituted systems: role of the molecular chaperone hsp90.
Goasduff T; Cederbaum AI
Arch Biochem Biophys; 2000 Jul; 379(2):321-30. PubMed ID: 10898951
[TBL] [Abstract][Full Text] [Related]
5. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
[TBL] [Abstract][Full Text] [Related]
6. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
Schumacher JA; Crockett DK; Elenitoba-Johnson KS; Lim MS
Proteomics; 2007 Aug; 7(15):2603-16. PubMed ID: 17610208
[TBL] [Abstract][Full Text] [Related]
7. Distinct regulation of insulin receptor substrate-1 and -2 by 90-kDa heat-shock protein in adrenal chromaffin cells.
Yoshikawa N; Nemoto T; Satoh S; Maruta T; Yanagita T; Chosa E; Wada A
Neurochem Int; 2010 Jan; 56(1):42-50. PubMed ID: 19737590
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin.
Ohji G; Hidayat S; Nakashima A; Tokunaga C; Oshiro N; Yoshino K; Yokono K; Kikkawa U; Yonezawa K
J Biochem; 2006 Jan; 139(1):129-35. PubMed ID: 16428328
[TBL] [Abstract][Full Text] [Related]
11. Inside the Hsp90 inhibitors binding mode through induced fit docking.
Lauria A; Ippolito M; Almerico AM
J Mol Graph Model; 2009 Feb; 27(6):712-22. PubMed ID: 19084447
[TBL] [Abstract][Full Text] [Related]
12. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90.
Itoh H; Ogura M; Komatsuda A; Wakui H; Miura AB; Tashima Y
Biochem J; 1999 Nov; 343 Pt 3(Pt 3):697-703. PubMed ID: 10527951
[TBL] [Abstract][Full Text] [Related]
13. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
[TBL] [Abstract][Full Text] [Related]
15. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells.
Fang S; Fu J; Yuan X; Han C; Shi L; Xin Y; Luo L; Yin Z
Cell Immunol; 2009; 259(1):49-55. PubMed ID: 19560753
[TBL] [Abstract][Full Text] [Related]
17. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
18. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of macbecin as an Hsp90 inhibitor.
Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]